THE CONFERENCE

The 1st annual conference, powered by Life Sciences Nova Scotia, is set to unravel the dynamic landscape of precision medicine within the region, promising a journey through the latest advancements, challenges, and opportunities. The inaugural event will be dedicated to facilitating discussions on the forefront of precision medicine – delivering the right treatment to the right patient at the right time – in Atlantic Canada.

OUR VISION

Gather esteemed experts, visionary administrators, dedicated clinicians, innovative researchers, and empowered patients, all driven by a shared mission to chart the course of Precision Medicine in Atlantic Canada.

Through collaborative exploration, attendees will delve into opportunities and solutions aimed at instigating genuine progress and transformative change. Additionally, the event will the event will focus on the strengths and opportunities in Atlantic Canada ensuring patient access equity in the region.

THE EXPERIENCE

We will embark on a journey of discovery, exploration, and transformation at the forefront of precision medicine in Atlantic Canada!

Together we will delve into the intricate tapestry of precision medicine’s evolution, examining the transformative impact it has already made and the boundless potential it holds for the future of healthcare in our region.  Experience engaging keynotes, thought-provoking panel presentations and discussions, participants will have the opportunity to exchange insights, forge collaborations, and inspire action towards realizing the full potential of precision medicine in Atlantic Canada. From exploring cutting-edge technologies and methodologies to addressing regulatory and ethical considerations, this conference promises to be a catalyst for innovation, collaboration, and progress in the field of precision medicine.

THE EXPERIENCE

We will embark on a journey of discovery, exploration, and transformation at the forefront of precision medicine in Atlantic Canada!

Together we will delve into the intricate tapestry of precision medicine’s evolution, examining the transformative impact it has already made and the boundless potential it holds for the future of healthcare in our region.  Experience engaging keynotes, thought-provoking panel presentations and discussions, participants will have the opportunity to exchange insights, forge collaborations, and inspire action towards realizing the full potential of precision medicine in Atlantic Canada. From exploring cutting-edge technologies and methodologies to addressing regulatory and ethical considerations, this conference promises to be a catalyst for innovation, collaboration, and progress in the field of precision medicine.

OUR COMMITTEE

Anatomical and Molecular Pathologist, and Medical Director of Molecular Diagnostics at NSH Central

Michael D. Carter MD PhD FRCPC

Medical Oncologist and Clinician Scientist with Newfoundland and Labrador Health Services, Clinical Assistant Professor in the Disciplines of Oncology and Laboratory Medicine at Memorial University, and Oncology Lead at the Centre for Translational Genomics

Dr. Angela Hyde MD, Ph.D.

Medical Director Molecular Genetics Laboratory, Dr. G. L. Dumont University Hospital Senior Scientist, Atlantic Cancer Research Institute R.R. Leger/NBHRF Chair in Precision Cancer Research. Adjunct Professor of Biochemistry, Université de Moncton

Dr. Rodney Ouellette, MD, PhD

Associate Professor in the Division of Medical Oncology at Dalhousie University

Dr. Ravi Ramjeesingh MD, Ph.D., FRCPC

Medical Oncologist, QEII Health Sciences Centre / Professor, Faculty of Medicine, Dalhousie University / President Lung Cancer Canada

Stephanie Snow MD FRCPC

President & CEO, LungNSPEI

Robert MacDonald

Vice President Business Development & Strategy - Life Sciences Nova Scotia

Doris Grant

Business Development Coordinator with the Nova Scotia Health Innovation Hub

Noel Guscott

Anatomical and Molecular Pathologist, and Medical Director of Molecular Diagnostics at NSH Central

Michael D. Carter MD PhD FRCPC

Dr. Carter completed medical school at the University of Toronto, followed by residency training in Anatomical Pathology at Dalhousie University and a 1-year fellowship in Molecular Genetic Pathology at the University of Michigan in Ann Arbor, MI.  He began as an Anatomical and Molecular Pathologist at NSH Central Zone and Assistant Professor of Pathology at Dalhousie University in 2018 and, in July 2021, was appointed Medical Director of Molecular Diagnostics at NSH. He is also Medical Director of Research, Division of Anatomical Pathology, and co-chair of the Molecular Oncology Diagnostic Testing Provincial Stewardship Committee for NSH.

Medical Oncologist and Clinician Scientist with Newfoundland and Labrador Health Services, Clinical Assistant Professor in the Disciplines of Oncology and Laboratory Medicine at Memorial University, and Oncology Lead at the Centre for Translational Genomics

Dr. Angela Hyde MD, Ph.D.

Angela Hyde completed her MD and PhD in Cancer Genetics at Memorial University of Newfoundland, then Internal Medicine residency at Memorial and Medical Oncology at the University of Ottawa. She is a Medical Oncologist and Clinician Scientist with Newfoundland and Labrador Health Services, Clinical Assistant Professor in the Disciplines of Oncology and Laboratory Medicine at Memorial University, and Oncology Lead at the Centre for Translational Genomics.  Her clinical focus is gastrointestinal malignancies and hereditary cancers. She is co-lead on numerous clinical and research initiatives relating to cancer genetics/genomics and hereditary cancer syndromes.

Medical Director Molecular Genetics Laboratory, Dr. G. L. Dumont University Hospital Senior Scientist, Atlantic Cancer Research Institute R.R. Leger/NBHRF Chair in Precision Cancer Research. Adjunct Professor of Biochemistry, Université de Moncton

Dr. Rodney Ouellette, MD, PhD

As the founding Scientific Director of the Atlantic Cancer Research Institute and the Molecular Genetics Laboratory, he has dedicated over 25 years to clinical molecular diagnostics and precision medicine research, specializing in liquid biopsy technologies for cancer. He has authored over 75 scientific articles and secured tens of millions in research funding for the region.

Associate Professor in the Division of Medical Oncology at Dalhousie University

Dr. Ravi Ramjeesingh MD, Ph.D., FRCPC

Dr. Ramjeesingh is an Associate Professor in the Division of Medical Oncology at Dalhousie University. He completed his MD (2008) and Ph.D in cancer research (2004) at the University of Toronto. He completed his residencies at Queen’s University and a clinical trials methodology fellowship at the Canadian Cancer Trials Group (CCTG). His main clinical expertise is in hepatopancreobiliary (HPB) and breast cancers. He is the chair of the HPB Disease site group in Nova Scotia, the Director of Research for Medical Oncology Nova Scotia and the Medical Director of the Nova Scotian oncology clinical trials group (ACCRU). His main research focus is in real world evidence of HPB cancer and translational research in Pancreatic Cancer.

Medical Oncologist, QEII Health Sciences Centre / Professor, Faculty of Medicine, Dalhousie University / President Lung Cancer Canada

Stephanie Snow MD FRCPC

Dr. Stephanie Snow is a staff Medical Oncologist at the QEII hospital in Halifax, Nova Scotia.  After pursuing undergraduate training at McGill, she completed her training at Dalhousie, where she is now a full professor in the Faculty of Medicine.  Dr. Snow has a strong interest in Medical Education and is Vice Chair of the Royal College Medical Oncology Examination Board.  Finally, Dr. Snow is active in patient advocacy, serving as the current President of Lung Cancer Canada, and sits on the medical advisory committees of several other patient advocacy groups in colorectal and gastric cancer.

President & CEO, LungNSPEI

Robert MacDonald

Robert’s professional career has spanned the private, public, and no-profit sectors. Over the last 13 years, he has been with the Lung Association, first as a Health Initiatives Manager and the last 7 years as President & CEO. During his tenure as CEO, he has greatly improved the organization’s finances, increased staff retention, improved programming, and has grown the organization through a merger with the PEI Lung Association. Prior to his, he worked in the Nova Scotia Premier’s Office. He is passionate about continuing to improve lung health in both NS and PEI through innovation and prevention. In his free time, he enjoys sports, reading, and the outdoors.

Vice President Business Development & Strategy - Life Sciences Nova Scotia

Doris Grant

For over 20 years, Doris has led commercialization, intellectual property protection and business development initiatives with a proven track record of building impactful partnerships and securing transformational funding to advance innovation mandates. Most recently Doris served as Senior Director of Innovation at Nova Scotia Health where she led the implementation of multiple high-priority, transformative and innovative initiatives to enhance healthcare and the health of Nova Scotians.

Business Development Coordinator with the Nova Scotia Health Innovation Hub

Noel Guscott

Noel is a Business Development Coordinator with the Nova Scotia Health Innovation Hub. He is a public policy and project management expert who currently supports a number of exciting health innovation initiatives across the province, including enhancements to the delivery of precision medicine in oncology at Nova Scotia Health. Noel’s career has spanned the public, academic and not-for-profit sectors, including serving as a full time soldier in the Canadian Army from 2014 to 2018 and other research, teaching and operational roles with employers such as Dalhousie University, the Nova Scotia College of Pharmacists, and Digital Nova Scotia. Noel is eager to build strategic partnerships to drive positive health system change and improve access to precision medicine at home, and across Canada.

SPEAKERS

We’re excited to unveil our diverse line up of speakers, featuring renowned experts in our industry. While some may already be familiar to you, others promise to bring new insights and discoveries to the table.

 

REGISTRATION

OUR SPONSORS

Thank You To Our BioPort 2023 Sponsors